MorphoSys Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/17/2024)
| Balance Sheet | Total Assets | 2,026,311,213.00 | ROE | – |
| Balance Sheet | Total Equity | 49,049,200.00 | ROA | – |
| Cashflow | Capital Expenditures | -2,872,691.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -298,709,634.00 | – | – |
| Cashflow | Operating Cash Flow | -295,837,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -5.53 | Div. Yield | – |
| Income | Net Income | -189,734,000.00 | P/E | – |
| Income | Shares Outstanding | 37,618,100.00 | P/B | – |
| Income | Total Revenue | 238,278,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Morphosys AG is a German biotechnology company focused on generation of fully human antibodies. It operates two business segments: Partnered Discovery and Proprietary Development. The Partnered Discovery business segment comprises technologies for the generation of human antibody therapeutics, which is exploited via partnerships with multiple pharmaceutical and biotechnology companies. The Proprietary Development business segment involves all activities relating to proprietary therapeutic antibody development, primarily including three main compounds in the Company's proprietary product portfolio, MOR103, MOR202 and MOR208, as well as five programs in the discovery phase and two pre-development programs with Novartis. On January 10, 2013, it announced the completion of the divestment of the AbD Serotec segment, which was engaged in the design and manufacture of antibodies for research and diagnostic purposes, including the Human Combinatorial Antibody Library ( HuCAL) technology
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.morphosys.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more